Imagion Biosystems Limited has lodged Appendix 4G “Key to Disclosures, Corporate Governance Council Principles and Recommendations” with the Australian Securities Exchange. Read Appendix 4G and Corporate Governance Statement.
Appendix 4G and Corporate Governance Statement
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.